glp-1 agonists for diabetes The Unstoppable Rise of Agonists: Revolutionising and Obesity Treatment Schematic illustration of monoagonists, dual

Al thow, M

doi:10.2337/db12-0230 55

In obesity care, the same agents are framed around weight reduction, cardiometabolic risk improvement, and, increasingly, quality of life

The dual GIP/GLP-1 receptor agonist has shown superior efficacy in weight reduction and metabolic improvement, and its European rollout marks a significant milestone in expanding the availability of next-generation obesity drugs beyond the U.S

Regulatory nods for Wegovy in Mexico and Brazil widen eligibility to millions of high-BMI adults, while cardiovascular-outcome data support use in secondary prevention

In -cells, the TATA box, as well as the adjacent G1 and G4 elements, represent the minimal promoter which is essential for Gcg expression while the elements G5, G2, G3, and CRE represent a more distal located enhancer region [94,[101], [102], [103]] (Figure 2)